The AFP data from pathology reports revealed that HBL patients with an active β-catenin-TCF4-CEGRs/ALCDs pathway had high levels of AFP protein in their serum samples, consistent with other reports that increased AFP is a signature of liver cancer. This evidence concerns the gene TCF4 and liver cancer.